Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_1

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

NCT00519259
unknownphase_1

Ph1 Lobeline Interaction Study - 1

NCT00439504
unknownphase_1

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074

Clinical Trials (3)

Showing 3 of 3 trials
NCT00519259Phase 1

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

Unknown
NCT00439504Phase 1

Ph1 Lobeline Interaction Study - 1

Unknown
NCT00100074Phase 1

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3